{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:34:00Z","timestamp":1772120040128,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["N41\/DBS\/000906"],"award-info":[{"award-number":["N41\/DBS\/000906"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl. Stroke Res."],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neutrophil-activating peptide 2 (NAP-2, CXCL7), a platelet-derived neutrophil chemoattractant, is involved in inflammation. We investigated associations between NAP-2 levels, neutrophil extracellular traps (NETs) formation, and fibrin clot properties in atrial fibrillation (AF).\u00a0We recruited 237 consecutive patients with AF (mean age, 68\u2009\u00b1\u200911\u00a0years; median CHA\n                    <jats:sub>2<\/jats:sub>\n                    DS\n                    <jats:sub>2<\/jats:sub>\n                    VASc score of 3 [2\u20134]) and 30 apparently healthy controls. Plasma NAP-2 concentrations were measured, along with plasma fibrin clot permeability (K\n                    <jats:sub>s<\/jats:sub>\n                    ) and clot lysis time (CLT), thrombin generation, citrullinated histone H3 (citH3), as a marker of NETs formation, and 3-nitrotyrosine reflecting oxidative stress.\u00a0NAP-2 levels were 89% higher in AF patients than in controls (626 [448\u2013796] vs. 331 [226\u2013430] ng\/ml; p\u2009&lt;\u20090.0001). NAP-2 levels were not associated with demographics, CHA\n                    <jats:sub>2<\/jats:sub>\n                    DS\n                    <jats:sub>2<\/jats:sub>\n                    -VASc score, or the AF manifestation. Patients with NAP-2 in the top quartile (&gt;\u2009796\u00a0ng\/ml) were characterized by higher neutrophil count (+\u200931.7%), fibrinogen (+\u200920.8%), citH3 (+\u200986%), and 3-nitrotyrosine (+\u2009111%) levels, along with 20.2% reduced K\n                    <jats:sub>s<\/jats:sub>\n                    and 8.4% prolonged CLT as compared to the remaining subjects (all p\u2009&lt;\u20090.05). NAP-2 levels were positively associated with fibrinogen in AF patients (r\u2009=\u20090.41, p\u2009=\u20090.0006) and controls (r\u2009=\u20090.65, p\u2009&lt;\u20090.01), along with citH3 (r\u2009=\u20090.36, p\u2009&lt;\u20090.0001) and 3-nitrotyrosine (r\u2009=\u20090.51, p\u2009&lt;\u20090.0001) in the former group. After adjustment for fibrinogen, higher citH3 (per 1\u00a0ng\/ml \u03b2\u2009=\u2009-0.046, 95% CI -0.029; -0.064) and NAP-2 (per 100\u00a0ng\/ml \u03b2\u2009=\u2009-0.21, 95% CI -0.14; -0.28) levels were independently associated with reduced K\n                    <jats:sub>s<\/jats:sub>\n                    .\u00a0Elevated NAP-2, associated with increased oxidative stress, has been identified as a novel modulator of prothrombotic plasma fibrin clot properties in patients with AF.\n                  <\/jats:p>","DOI":"10.1007\/s12975-023-01165-1","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T02:03:51Z","timestamp":1686276231000},"page":"773-783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neutrophil-activating Peptide 2 as a Novel Modulator of Fibrin Clot Properties in Patients with Atrial Fibrillation"],"prefix":"10.1007","volume":"15","author":[{"given":"Micha\u0142","family":"Z\u0105bczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Natorska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142 T.","family":"Matusik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrycja","family":"Mo\u0142ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiktoria","family":"Wojciechowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Rajzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Rajtar-Salwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Tokarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Lenart-Migdalska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Olszowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-8109","authenticated-orcid":false,"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"1165_CR1","doi-asserted-by":"crossref","unstructured":"Dong XJ, Wang BB, Hou FF, Jiao Y, Li HW, Lv SP, Li FH. Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2019. Europace. 2023:euac237 [in press].","DOI":"10.1093\/europace\/euac237"},{"key":"1165_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.33963\/KP.a2022.0202","volume":"81","author":"Z Kalarus","year":"2023","unstructured":"Kalarus Z, Sredniawa B, Mitrega K, Wierucki L, Sokal A, Lip G, Bandosz P, Stokwiszewski J, Boidol J, Zieleniewicz P, Rutkowski M, Kazmierczak J, Opolski G, Grodzicki T, Zdrojewski T. Prevalence of atrial fibrillation in Polish population \u226565 old. Report of cross-sectional NOMED-AF study. Kardiol Pol. 2023;81:14\u201321.","journal-title":"Kardiol Pol."},{"key":"1165_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/cvr\/cvy272","volume":"115","author":"AA Khan","year":"2019","unstructured":"Khan AA, Lip GYH. The prothrombotic state in atrial fibrillation: pathophysiological and management implications. Cardiovasc Res. 2019;115:31\u201345.","journal-title":"Cardiovasc Res"},{"key":"1165_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2022.02.025","volume":"213","author":"P Mo\u0142ek","year":"2022","unstructured":"Mo\u0142ek P, Z\u0105bczyk M, Malinowski KP, Natorska J, Undas A. Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state. Thromb Res. 2022;213:1\u20137.","journal-title":"Thromb Res"},{"key":"1165_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2022.07.034","volume":"365","author":"P Mo\u0142ek","year":"2022","unstructured":"Mo\u0142ek P, Chmiel J, Z\u0105bczyk M, Malinowski KP, Natorska J, Undas A. Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation. Int J Cardiol. 2022;365:1\u20137.","journal-title":"Int J Cardiol"},{"key":"1165_CR6","doi-asserted-by":"crossref","unstructured":"Z\u0105bczyk M, Ari\u00ebns RAS, Undas A. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice. Cardiovasc Res. 2023:cvad017 [in press].","DOI":"10.1093\/cvr\/cvad017"},{"key":"1165_CR7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1161\/ATVBAHA.119.313626","volume":"40","author":"JJ de Vries","year":"2020","unstructured":"de Vries JJ, Snoek CJM, Rijken DC, de Maat MPM. Effects of Post-Translational Modifications of Fibrinogen on Clot Formation, Clot Structure, and Fibrinolysis: A Systematic Review. Arterioscler Thromb Vasc Biol. 2020;40:554\u201369.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1165_CR8","doi-asserted-by":"publisher","first-page":"101344","DOI":"10.1016\/j.redox.2019.101344","volume":"28","author":"K Xie","year":"2020","unstructured":"Xie K, Varatnitskaya M, Maghnouj A, Bader V, Winklhofer KF, Hahn S, Leichert LI. Activation leads to a significant shift in the intracellular redox homeostasis of neutrophil-like cells. Redox Biol. 2020;28:101344.","journal-title":"Redox Biol"},{"key":"1165_CR9","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1161\/STROKEAHA.117.018143","volume":"48","author":"L Drabik","year":"2017","unstructured":"Drabik L, Wo\u0142kow P, Undas A. Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation. Stroke. 2017;48:2716\u201322.","journal-title":"Stroke"},{"key":"1165_CR10","doi-asserted-by":"crossref","unstructured":"Janion-Sadowska A, Chrapek M, Konieczy\u0144ska M, Undas A. Altered Fibrin Clot Properties Predict Stroke and Bleedings in Patients With Atrial Fibrillation on Rivaroxaban. Stroke. 2018;STROKEAHA118023712.","DOI":"10.1161\/STROKEAHA.118.023712"},{"key":"1165_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cjca.2019.08.001","volume":"36","author":"L Drabik","year":"2020","unstructured":"Drabik L, Konieczy\u0144ska M, Undas A. Clot Lysis Time Predicts Stroke During Anticoagulant Therapy in Patients with Atrial Fibrillation. Can J Cardiol. 2020;36:119\u201326.","journal-title":"Can J Cardiol"},{"key":"1165_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1034\/j.1600-065X.2000.17705.x","volume":"177","author":"E Brandt","year":"2000","unstructured":"Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev. 2000;177:204\u201316.","journal-title":"Immunol Rev"},{"key":"1165_CR13","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1182\/blood-2012-09-459636","volume":"121","author":"M Ghasemzadeh","year":"2013","unstructured":"Ghasemzadeh M, Kaplan ZS, Alwis I, Schoenwaelder SM, Ashworth KJ, Westein E, Hosseini E, Salem HH, Slattery R, McColl SR, Hickey MJ, Ruggeri ZM, Yuan Y, Jackson SP. The CXCR1\/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi. Blood. 2013;121:4555\u201366.","journal-title":"Blood"},{"key":"1165_CR14","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1160\/TH14-08-0662","volume":"113","author":"M Ghasemzadeh","year":"2015","unstructured":"Ghasemzadeh M, Hosseini E. Intravascular leukocyte migration through platelet thrombi: directing leukocytes to sites of vascular injury. Thromb Haemost. 2015;113:1224\u201335.","journal-title":"Thromb Haemost"},{"key":"1165_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12975-021-00938-w","volume":"13","author":"AM Kollikowski","year":"2022","unstructured":"Kollikowski AM, Pham M, M\u00e4rz AG, Papp L, Nieswandt B, Stoll G, Schuhmann MK. Platelet Activation and Chemokine Release Are Related to Local Neutrophil-Dominant Inflammation During Hyperacute Human Stroke. Transl Stroke Res. 2022;13:364\u20139.","journal-title":"Transl Stroke Res"},{"key":"1165_CR16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.jacc.2006.06.060","volume":"48","author":"C Smith","year":"2006","unstructured":"Smith C, Dam\u00e5s JK, Otterdal K, \u00d8ie E, Sandberg WJ, Yndestad A, Waehre T, Scholz H, Endresen K, Olofsson PS, Halvorsen B, Gullestad L, Fr\u00f8land SS, Hansson GK, Aukrust P. Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation. J Am Coll Cardiol. 2006;48:1591\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1535370218823684","volume":"244","author":"X Wang","year":"2019","unstructured":"Wang X, Li J, Gan L, Liu Q. Plasma NAP-2 levels are associated with critical limb ischemia in peripheral arterial disease patients. Exp Biol Med. 2019;244:22\u20137.","journal-title":"Exp Biol Med"},{"key":"1165_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jaut.2015.08.001","volume":"65","author":"MD Patsouras","year":"2015","unstructured":"Patsouras MD, Sikara MP, Grika EP, Moutsopoulos HM, Tzioufas AG, Vlachoyiannopoulos PG. Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome. J Autoimmun. 2015;65:30\u20137.","journal-title":"J Autoimmun"},{"key":"1165_CR19","doi-asserted-by":"publisher","first-page":"599363","DOI":"10.3389\/fonc.2020.599363","volume":"10","author":"L Li","year":"2021","unstructured":"Li L, Zhang L, Zhang T, Qi X, Cheng G, Xia L. Serum Chemokine CXCL7 as a Potential Novel Biomarker for Obstructive Colorectal Cancer. Front Oncol. 2021;10:599363.","journal-title":"Front Oncol"},{"key":"1165_CR20","doi-asserted-by":"publisher","first-page":"754221","DOI":"10.3389\/fonc.2021.754221","volume":"11","author":"L Li","year":"2021","unstructured":"Li L, Jiang K, Li D, Li D, Fan Z, Dai G, Tu S, Liu X, Wei G. The Chemokine CXCL7 Is Related to Angiogenesis and Associated With Poor Prognosis in Colorectal Cancer Patients. Front Oncol. 2021;11:754221.","journal-title":"Front Oncol"},{"key":"1165_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13613-021-00899-1","volume":"11","author":"N Yatim","year":"2021","unstructured":"Yatim N, Boussier J, Chocron R, Hadjadj J, Philippe A, Gendron N, Barnabei L, Charbit B, Szwebel TA, Carlier N, P\u00e8ne F, Azoulay C, Khider L, Mirault T, Diehl JL, Guerin CL, Rieux-Laucat F, Duffy D, Kern\u00e9is S, Smadja DM, Terrier B. Platelet activation in critically ill COVID-19 patients. Ann Intensive Care. 2021;11:113.","journal-title":"Ann Intensive Care"},{"key":"1165_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373\u2013498.","journal-title":"Eur Heart J"},{"key":"1165_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"1165_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000073575","volume":"32","author":"HC Hemker","year":"2002","unstructured":"Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32:249\u201353.","journal-title":"Pathophysiol Haemost Thromb"},{"key":"1165_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/blood-2016-05-718114","volume":"128","author":"LL Swystun","year":"2016","unstructured":"Swystun LL, Liaw PC. The role of leukocytes in thrombosis. Blood. 2016;128:753\u201362.","journal-title":"Blood"},{"key":"1165_CR26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3389\/fimmu.2017.01248","volume":"8","author":"AJ Brown","year":"2017","unstructured":"Brown AJ, Sepuru KM, Sawant KV, Rajarathnam K. Platelet-Derived Chemokine CXCL7 Dimer Preferentially Exists in the Glycosaminoglycan-Bound Form: Implications for Neutrophil-Platelet Crosstalk. Front Immunol. 2017;8:1248.","journal-title":"Front Immunol"},{"key":"1165_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cellsig.2018.11.004","volume":"54","author":"K Rajarathnam","year":"2019","unstructured":"Rajarathnam K, Schnoor M, Richardson RM, Rajagopal S. How do chemokines navigate neutrophils to the target site: Dissecting the structural mechanisms and signaling pathways. Cell Signal. 2019;54:69\u201380.","journal-title":"Cell Signal"},{"key":"1165_CR28","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.thromres.2015.05.028","volume":"136","author":"L Drabik","year":"2015","unstructured":"Drabik L, Wo\u0142kow P, Undas A. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation. Thromb Res. 2015;136:408\u201314.","journal-title":"Thromb Res"},{"key":"1165_CR29","first-page":"1112","volume":"7","author":"F Violi","year":"2014","unstructured":"Violi F, Pastori D, Pignatelli P. Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation. J Atr Fibrillation. 2014;7:1112.","journal-title":"J Atr Fibrillation"},{"key":"1165_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/01.CIR.104.2.174","volume":"104","author":"MJ Mihm","year":"2001","unstructured":"Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104:174\u201380.","journal-title":"Circulation"},{"key":"1165_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1161\/01.CIR.95.2.489","volume":"95","author":"S Ishiyama","year":"1997","unstructured":"Ishiyama S, Hiroe M, Nishikawa T, Abe S, Shimojo T, Ito H, Ozasa S, Yamakawa K, Matsuzaki M, Mohammed MU, Nakazawa H, Kasajima T, Marumo F. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation. 1997;95:489\u201396.","journal-title":"Circulation"},{"key":"1165_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ijcard.2008.04.012","volume":"135","author":"DI Leftheriotis","year":"2009","unstructured":"Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT, Venetsanou KS, Iliodromitis EK, Kremastinos DT. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol. 2009;135:361\u20139.","journal-title":"Int J Cardiol"},{"key":"1165_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijcard.2008.02.026","volume":"130","author":"W Han","year":"2008","unstructured":"Han W, Fu S, Wei N, Xie B, Li W, Yang S, Li Y, Liang Z, Huo H. Nitric oxide overproduction derived from inducible nitric oxide synthase increases cardiomyocyte apoptosis in human atrial fibrillation. Int J Cardiol. 2008;130:165\u201373.","journal-title":"Int J Cardiol"},{"key":"1165_CR34","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.thromres.2012.03.017","volume":"130","author":"M Bijak","year":"2012","unstructured":"Bijak M, Nowak P, Borowiecka M, Ponczek MB, \u017bbikowska HM, Wachowicz B. Protective effects of (-)-epicatechin against nitrative modifications of fibrinogen. Thromb Res. 2012;130:e123\u20138.","journal-title":"Thromb Res"},{"key":"1165_CR35","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1161\/hc4901.101760","volume":"104","author":"MK Chung","year":"2001","unstructured":"Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886\u201391.","journal-title":"Circulation"},{"key":"1165_CR36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.20452\/pamw.1101","volume":"121","author":"M Z\u0105bczyk","year":"2011","unstructured":"Z\u0105bczyk M, Majewski J, Lelakowski J. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation. Pol Arch Med Wewn. 2011;121:400\u20137.","journal-title":"Pol Arch Med Wewn"},{"key":"1165_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijcard.2017.05.060","volume":"243","author":"PT Matusik","year":"2017","unstructured":"Matusik PT, Matusik PS, Kornacewicz-Jach Z, Ma\u0142ecka B, Z\u0105bek A, Undas A. Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation. Int J Cardiol. 2017;243:244\u201350.","journal-title":"Int J Cardiol"},{"key":"1165_CR38","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.thromres.2011.07.013","volume":"128","author":"M Hayashi","year":"2011","unstructured":"Hayashi M, Takeshita K, Inden Y, Ishii H, Cheng XW, Yamamoto K, Murohara T. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: involvement of mononuclear cell-platelet interaction. Thromb Res. 2011;128:e113-118.","journal-title":"Thromb Res"},{"key":"1165_CR39","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1161\/ATVBAHA.107.152777","volume":"27","author":"D Ferro","year":"2007","unstructured":"Ferro D, Loffredo L, Polimeni L, Fimognari F, Villari P, Pignatelli P, Fuster V, Violi F. Soluble cd40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol. 2007;27:2763\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1165_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/eurheartj\/ehi645","volume":"27","author":"CJ Boos","year":"2006","unstructured":"Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27:136\u201349.","journal-title":"Eur Heart J"},{"key":"1165_CR41","doi-asserted-by":"publisher","first-page":"e148668","DOI":"10.1172\/jci.insight.148668","volume":"6","author":"A Chrysanthopoulou","year":"2021","unstructured":"Chrysanthopoulou A, Gkaliagkousi E, Lazaridis A, Arelaki S, Pateinakis P, Ntinopoulou M, Mitsios A, Antoniadou C, Argyriou C, Georgiadis GS, Papadopoulos V, Giatromanolaki A, Ritis K, Skendros P. Angiotensin II triggers release of neutrophil extracellular traps, linking thromboinflammation with essential hypertension. JCI Insight. 2021;6:e148668.","journal-title":"JCI Insight"},{"key":"1165_CR42","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1538-7836.2006.01882.x","volume":"4","author":"A Undas","year":"2006","unstructured":"Undas A, Celinska-L\u00f6wenhoff M, L\u00f6wenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006;4:1029\u201336.","journal-title":"J Thromb Haemost"},{"key":"1165_CR43","first-page":"16252","volume":"132","author":"L Xu","year":"2022","unstructured":"Xu L, Fan T, Liang Y, Zhou C, Chen X, Yuan W. Association between interleukin 17A levels and left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation. Pol Arch Intern Med. 2022;132:16252.","journal-title":"Pol Arch Intern Med"}],"container-title":["Translational Stroke Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-023-01165-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12975-023-01165-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-023-01165-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T20:20:56Z","timestamp":1729542056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12975-023-01165-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s12975-023-01165-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2660447\/v1","asserted-by":"object"}]},"ISSN":["1868-4483","1868-601X"],"issn-type":[{"value":"1868-4483","type":"print"},{"value":"1868-601X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"6 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.U. receives lecture honoraria from Bayer, Pfizer, and Boehringer Ingelheim. P.T.M. received speech honorarium from Boehringer Ingelheim, Polish Cardiac Society 2018 Scientific Grant in cooperation with Berlin-Chemie\/Menarini (sponsor of the grant: Berlin-Chemie\/Menarini Poland LLC) and participated in educational activities which were supported by Polpharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}